Omega-3 fatty acids for uremic pruritus: A meta-analysis of randomized controlled trials

Uremic pruritus (UP) is common in the late stages of chronic kidney disease. Currently, there is a lack of effective treatment for UP. Limited evidence exists on the therapeutic effect of omega-3 fatty acid (O3FA). The aim of this study was to evaluate the efficacy of O3FA supplements in UP patients....

Full description

Saved in:
Bibliographic Details
Published inCi ji yi xue za zhi Vol. 34; no. 4; pp. 394 - 401
Main Authors Lu, Ping-Hsun, Yao, Xiao-Feng, Lin, Yang-Sheng, Tzeng, I-Shiang, Lu, Po-Hsuan, Kuo, Ko-Lin
Format Journal Article
LanguageEnglish
Published India Wolters Kluwer - Medknow Publications 01.10.2022
Medknow Publications and Media Pvt. Ltd
Wolters Kluwer - Medknow
Wolters Kluwer Medknow Publications
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Uremic pruritus (UP) is common in the late stages of chronic kidney disease. Currently, there is a lack of effective treatment for UP. Limited evidence exists on the therapeutic effect of omega-3 fatty acid (O3FA). The aim of this study was to evaluate the efficacy of O3FA supplements in UP patients. We evaluated the efficacy of O3FA supplements in patients with UP through a systematic review and a meta-analysis of randomized control trials retrieved from PubMed, Embase, Cochrane Library, CINAHL, and ClinicalTrials.gov databases. The included studies were summarized and assessed for the risk of bias, and pruritus assessment results were analyzed. To compared with a controlled group, five articles including 164 participants published between 2012 and 2019 using different pruritus scales reported that patients taking O3FA supplement exhibited no significant decrease in the pruritus score (standardized mean difference [SMD] =1.34, 95% confidence interval [CI] = −2.70-0.01, P = 0.05), but three articles using same pruritus scale significant decrease Duo pruritus score (SMD = −0.85, 95% CI = −1.39 to −0.30, P < 0.05). O3FA supplement could be an appealing complementary therapy for UP patients. More rigorously designed studies are needed before recommending the O3FA supplement.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1016-3190
2223-8956
2223-8956
DOI:10.4103/tcmj.tcmj_221_21